Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 551 - 600 out of 106,113

Document Document Title
WO/2015/011451A1
Compositions for use in a method of treatment, particularly for use in a method of treatment of epilepsy or an epilepsy-related disorder, are provided. Uses of the compositions are also described, along with methods for employing the com...  
WO/2015/010217A1
Dimiracetam or a solvate thereof is a suitable effective substance for being used in the treatment and/or prevention of depression.  
WO/2015/012780A1
The invention relates to medicine and the chemical and pharmaceutical industry, and more particularly to the creation, production and use of cerebroprotective agents for improving cerebral blood flood. The medicinal agent contains (in gr...  
WO/2015/013451A3
Provided are methods for enhancing hippocampal plasticity and hippocampal-mediated learning and memory, and/or enhancing the synaptic maturation of neurons, and/or optimizing or enhancing neuronal synaptic transmission, and/or enhancing ...  
WO/2015/011246A1
The present invention relates to the use of flecainide as an anti-connexin agent. This anti-connexin agent is advantageously used to potentiate the therapeutic effectof various psychotropic drugs. More specifically, the invention provide...  
WO/2015/011447A1
Provided are methods and materials for treating a neurological, behavioural, psychological, psychiatric, or personality disorder or syndrome in an individual, which disorder or syndrome is associated with a plurality of aberrant thoughts...  
WO/2015/012298A1
A compound represented by general formula (I) (I) has a strong Axl inhibiting activity by introducing a distinctive bicyclic structure in which a saturated carbocyclic ring is fused to a pyridone ring, and thus may be used as a therapeut...  
WO/2015/013318A1
This invention provides novel compounds of the following formula and pharmaceutical compositions containing such compounds.  
WO/2015/009195A1
The invention relates to novel substances, and more particularly to optical isomers of (+) and (-)-benzhydryl ureas of formula (I) and (+) and (-)-1-[(3-chlorophenyl)-phenyl-methyl] urea, a pharmaceutical composition based thereon, and a...  
WO/2015/010054A3
Described herein are neuroactive steroids of the Formula (I): (Formula (I)) or a pharmaceutically acceptable salt thereof; wherein R1a and R1b are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GAB...  
WO/2015/008073A1
The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 and n are defined herein, and their use in treating, preventing, ameliorating, controlling or reducing the risk of inflammation, neurological or psychi...  
WO/2015/009710A1
The present invention generally relates to compositions, reagents and methods for detecting and treating a neural tube defect in a fetus. One aspect of the invention provides a method including administrating a composition containing nog...  
WO/2015/008848A1
A self-emulsifying composition which comprises, when taking the total amount of the self-emulsifying composition as 100mass%, 70 to 90mass% of at least one compound selected from the group consisting of ω-3 polyunsaturated fatty acids, ...  
WO/2015/007249A1
An N-alkyl tryptanthrin derivative, a preparation method for same, and an application thereof. The structure of the derivative is as represented by formula I. The N-alkyl tryptanthrin derivative can serve as a highly active IDO inhibitor...  
WO/2015/009500A1
Anatabine is delivered in a volatilized form for treating substance addictions such as nicotine addiction, alcohol addiction, marijuana addiction, heroin addiction, or cocaine addiction. Devices such as electronic inhalers may be used fo...  
WO/2015/009008A1
The present invention relates to a novel adenine derivative and a pharmaceutical use thereof and, more specifically, to a novel adenine derivative having a structure of chemical formula 1 or a pharmaceutically acceptable salt thereof and...  
WO/2015/007191A1
The present invention belongs to pharmaceutical chemistry field. Paliperidone amino acids derivates and use thereof are disclosed After experiment, it is found that the compounds can be used for preparing medicant for treating mental dis...  
WO/2015/006829A1
The invention relates to a composition or method for treating at least one of infection, sepsis and injury or inducing a hypotensive state or a low pain or analgesic state in a subject susceptible to or suffering from at least one of inf...  
WO/2015/008206A1
The present invention provides compounds acting as Insulin/IGF signaling modulators useful in the treatment of neurodegenerative diseases and disorders. The invention provides pharmaceutical compositions including such compounds, and met...  
WO/2015/008849A1
A self-emulsifying composition which comprises, when taking the total amount of the composition as 100mass%, 70 to 90mass% of at least one compound selected from the group consisting of ω-3 polyunsaturated fatty acids, pharmaceutically ...  
WO/2015/007222A1
Provided is the discovery of the role of EphA4 signaling in neurodegenerative disorders involving β-amyloid induced neurotoxicity such as Alzheimer's Disease. New therapeutic methods, therapeutic agents, and kits for treating diseases c...  
WO/2015/009909A1
Generally provided herein are methods, compounds, and compositions described useful for the treatment of light chain amyloidosis and other amyloid protein diseases.  
WO/2015/007730A1
The present invention relates to compounds which are inhibitors of non-apoptotic regulated cell death, and to pharmaceutical compositions containing such compounds. Furthermore, the present invention relates to the use of such compounds ...  
WO/2015/009952A1
The invention provides a herpes simplex virus (HSV) vector that does not express toxic HSV genes in non-complementing cells and which comprises a genome comprising one or more transgenes, wherein the vector is capable of expression of a ...  
WO/2015/006827A1
The invention relates to a composition and method for inducing whole-body arrest, a coma-like state or a sleep state, a hypotensive state or a low pain or analgesic state. The composition comprises (i) a compound selected from at feast o...  
WO/2015/008861A1
Provided are: a compound represented by formula (1) or a pharmaceutically acceptable salt thereof; and a therapeutic agent for all of pathologic conditions in which Nav1.7 or Nav1.8 is concerned, specifically, for diseases such as neurop...  
WO/2015/008317A1
The present invention addresses the problem of providing a hydrogen sulfide production-inducing agent that has a higher efficiency and a lower toxicity than L-cysteine. The present invention is characterized in that, by administering D-c...  
WO/2015/007613A1
The present invention provides compounds of formula I and pharmaceutical compositions for inhibiting fatty acid amide hydrolase (FAAH). Inhibition of FAAH is contemplated as a method to sustain the levels of the fatty acid ethanolamides ...  
WO/2015/008827A1
A benzopyran derivative represented by general formula [1], or a salt thereof, is useful in therapeutic or preventive treatment of disease, wherein said therapeutic or preventive treatment is effective because said benzopyran derivative,...  
WO/2015/007615A1
The invention provides compounds of Formula (I) or pharmaceutically acceptable salts thereof wherein Ar', R1, R2, R3, R4, X, Y are as defined in the description of invention, as multi-target directed ligands (MTDLs) that are at the same ...  
WO/2015/007129A1
The present invention relates to a method for preparing (-)-huperzine A. The method involves: allowing (±)- huperzine A mixture obtained from chemical synthesis and a chiral acid to form (±)-huperzine A chiral acid salt under suitable ...  
WO/2015/004007A1
The present invention relates to ethynyl derivatives of formula (I) wherein Y is N or CH; R1 is hydrogen, fluoro or chloro; and R2 is hydrogen or lower alkyl; or to a pharmaceutically acceptable acid addition salt thereof. It has now sur...  
WO/2015/006315A1
The present invention relates to new dihydoxyphenyl modulators of neurotransmitter levels, pharmaceutical compositions thereof, and methods of use thereof.  
WO/2015/004464A1
The invention provides a polypeptide, for use in suppressing or treating itch, wherein the polypeptide comprises: a non-cytotoxic protease, which protease is capable of cleaving a SNARE protein in an itch-specific DRG neuron or a prurice...  
WO/2015/006280A1
The invention relates to fused piperidine amides useful as inhibitors of ion channels for the treatment of pain. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods o...  
WO/2015/006685A1
The present invention relates to a method for promoting cessation or reduction in the smoking and/or chewing of tobacco or nicotine-containing products in a subject in need thereof, comprising administering to the subject an effective am...  
WO/2015/003625A1
The present invention belongs to the field of pharmaceuticals and chemicals, and relates to thiazole inner salt compounds, and a preparation method and use thereof. In particular, the present invention relates to compounds as shown by fo...  
WO/2015/005458A1
The present invention provides a glycosaminoglycan derivative such that a group derived from glycosaminoglycan and a group deriving from a physiologically active substance having a carboxyl group and/or a hydroxyl group are coupled by co...  
WO/2015/003223A1
The present invention relates generally to compounds that are useful in antagonizing the angiotensin II type 2 (AT2) receptor. More particularly, the invention relates to substituted isoquinoline compounds and their use as AT2 receptor a...  
WO/2015/004163A1
The invention provides for tau antibodies, antibody-like scaffolds or antibody fragments with improved binding capacity for tau antigen. In particular, the invention provides for improved compositions, methods and kits comprising such an...  
WO/2015/004093A1
The present disclosure relates to the anticonvulsant activity of S. miltiorrhiza and tanshinones, and the use of compounds from S. miltiorrhiza as anticonvulsant agents for the treament of epilepsy and neurological disorders characterize...  
WO/2015/004485A1
The present invention relates to therapeutic compounds useful for the treatment of neurodegenerative and neuromuscular diseases and/or triplet repeat diseases (e.g. Friedreich's ataxia). The compounds have the structural formula I shown ...  
WO/2015/004240A1
The present invention relates to new nalmefene salts which salts fall within at least one of the two following categories: non-hydrate forming salts and non-solvate forming salts. In particular, the invention relates to the hydrogen adip...  
WO/2015/004371A1
The invention relates to a gaseous medication containing xenon, preferably in an amount of less than 75% by volume, for use by inhalation, in combination with at least one NMDA receptor antagonist in the form of a liquid or solid, in par...  
WO/2015/006280A9
The invention relates to fused piperidine amides useful as inhibitors of ion channels for the treatment of pain. The invention also provides pharmaceutically acceptable compositions comprising the compounds of the invention and methods o...  
WO/2015/006569A2  
WO/2015/005459A1
 The present invention provides a pharmaceutical composition for respiratory administration containing a polysaccharide derivative having a group derived from a polysaccharide and a group derived from a biologically active substance co...  
WO/2015/005562A1
The present invention provides a composition including, as active ingredients, anthocyanin and a GABAB1R receptor agonist for providing effects for preventing and treating neurological disorders which are caused by nerve cell apoptosis, ...  
WO/2015/005491A1
Provided are a compound and a medicinal composition relating to a disease in which an abnormal splice variant participates, utilization of the same, and a method for searching for the same. In one or more embodiments, provided is a compo...  
WO/2015/004347A1
The invention relates to a gaseous medication containing xenon, to be used by inhalation for treating, slowing or preventing neurological deterioration resulting from Parkinson's disease in a human patient. The medication preferably cont...  

Matches 551 - 600 out of 106,113